The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. After-hours trades for ACADIA Pharmaceuticals Inc. (ACAD) shows that investor sentiment remained broken, with the stock’s consolidated last price falling by -$0.11, or -0.51%, to $21.64. The ACADIA Pharmaceuticals Inc. has recorded 29,720 volume in the after hours trading session. Most recently, Yahoo Finance reported about the stock as it publicized that Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 8, 2023.
Unlock the Hottest Top 10 Penny Stocks Today! Discover Now
Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.
Gain Access to Top 10 Penny Stocks Now!.
ACADIA Pharmaceuticals Inc. is listed on the NASDAQ as a member of the Healthcare sector and is a part of the Biotechnology industry. At the end of the last regular session, the stock closed at $21.75 and fluctuated between $21.86 as its day high and $21.16 as its day low. The current market capitalization of ACADIA Pharmaceuticals Inc. is $3.39B. A total of 1.24 million shares were traded on the day, compared to an average of 1.57M shares.
Additionally, investors take into account insider trades when predicting how a stock will perform. During the recent three months, ACAD has seen 11 BUY and 11 SELL insider trades, representing the acquisition of 52,362 and the disposition of 20,971 shares. Over the last 12 months, there were 23 BUYs and 23 SELLs from insiders. Insiders purchased 158,567 shares during that period but sold 54,920.
In the most recent transaction, Kihara James sold 523 shares of ACAD for 18.14 per share on Apr 10. After the transaction, the Principal Accounting Officer now owns 5,197 company shares. In a previous transaction on Apr 06, DAVIS STEPHEN sold 8,582 shares at 18.16 per share. ACAD shares that CEO owns now total 100,478.
Among the insiders who sold shares, Schneyer Mark C. disposed of 1,916 shares on Apr 06 at a per-share price of $18.16. This resulted in the EVP, Chief Financial Officer holding 7,477 shares of ACAD after the transaction. In another insider transaction, Teehan Brendan sold 1,751 shares at $18.16 per share on Apr 06. Company shares held by the EVP, COO, Head of Commercial now total 8,468.
Though price targets are rarely accurate, they can exert some influence from time to time and were often accepted as valuable by the market. According to analysts who have offered 12-month price targets for ACAD in the last 3 months, the mean price target is $22.61 with high estimates of $33.00 and low estimates of $12.00. In terms of 52-week highs and lows, ACAD has a high of $21.87 and a low of $12.24.
As of this writing, ACAD has an earnings estimate of -$0.21 per share for the current quarter. EPS was calculated based on a consensus of 18 estimates, with a high estimate of -$0.14 per share and a lower estimate of -$0.29. The company reported an EPS of -$0.17 in the last quarter, which was 10.50% higher than expectations of -$0.19.
Balance Sheet Annually/Quarterly
A balance sheet is a report that shows the company’s assets and liabilities. In addition, it shows how much equity investors have invested in the company. Investors can determine the company’s prospects by calculating its financial ratios based on this information. ACAD’s latest balance sheet shows that the firm has $520.71M in Cash & Short Term Investments as of fiscal 2021. There were $56.13M in debt and $96.07M in liabilities at the time. Its Book Value Per Share was $2.47, while its Total Shareholder’s Equity was $540.89M.
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Currently, 20 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for ACAD is Sell with a score of 3.44. A total of 8 analysts rated the stock as Buy while 0 rated it as Overweight while 10 rated it as Hold. Among the other participants, 0 thought the stock was Underweight and 2 thought it should be Sold.